Hasten Pharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing novel small molecule drugs for metabolic and cardiovascular diseases.
Metabolic DiseasesCardiovascular Diseases
Technology Platform
Small molecule drug discovery platform focused on structure-based design and optimization for metabolic and cardiovascular targets.
Opportunities
Large and growing patient population in China for metabolic disorders provides a substantial addressable market.
Risk Factors
Clinical failure of its lead candidates would significantly devalue the company given its focused pipeline.
Competitive Landscape
Faces intense competition from large pharma and other biotechs in the crowded metabolic disease space, requiring clear differentiation.